A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Associate Director - CMC Technology Delivery

Enterprise ApplicationsConfirmed live in the last 24 hours
Full-timeCambridge, MA, USA$172.2k - $233k

About the Job

Requirements

  • Bachelor’s degree in Science, Engineering, Information Technology, or a related field.
  • At least 10 years of experience in CMC, Process Engineering, or IT client-facing roles for CMC and Process/Analytical Development organizations in the biopharmaceutical or life sciences industry.
  • Experience with regulatory filing processes; recipe unit operations and data structures; statistical software and analytical trending tools, including multivariate data analysis, assay and control charts, JMP, Minitab, R, Python, SIMCA batch-on line, or SEEQ.
  • Experience with data and systems integration, analytics, working with system integrators, and managing IT suppliers.
  • Experience in regulated environments, including GxP, computer systems validation, and FDA 21 CFR regulations.
  • Knowledge of the full System Development Life Cycle, including requirements, design, implementation, integration and testing, release and deployment, operations and maintenance, and decommissioning.
  • Demonstrated success building and leading cross-functional teams.
  • Approximately 10% travel may be required.

Responsibilities

  • Define and execute the IT solutions roadmap aligned with business priorities and digital transformation goals for CMC organizations.
  • Oversee implementation and lifecycle management of digital CMC solutions that accelerate new pipeline products from Development Candidate declaration through Investigational New Drug and New Drug Application filings to commercial launch.
  • Drive digital and AI/ML capabilities for faster regulatory authoring, digital tech transfer of drug substance, drug product, analytical methods and data, and insight generation through data access and analytics.
  • Collaborate with CMC and IT Data/AI teams to create, transform, and store process recipe master and reference data, transactional data from lab, design of experiment, and batch execution runs, and derived data from statistical processing and trending.
  • Deploy capabilities to structure and standardize process recipe data for Critical Process Parameters, Critical Quality Attributes, In-Process Control parameters, Normal Operating Ranges, Proven Acceptable Ranges, and recipe version management as chemistry transfers through development, characterization, site characterization, and Process Performance Qualifications.
  • Partner to develop data assets and AI/digital capabilities for CMC statistics in Process Development and Characterization and Process and Product Control strategy, and implement and support lifecycle management of trending tools.
  • Enable digital capabilities for CMC Program Management, including transfers from R&D to CMC, program start-up and advancement, and status reporting.
  • Partner with CMC, external Contract Manufacturing Organizations, software and services partners, and internal IT to develop data products, process templates, procedures, and system integrations using API/EDI for process-data exchange.
  • Increase user adoption of data, AI, digital, and statistical analytics capabilities across research trending, Process Flow Descriptions, regulatory specification filing, control strategy drafting, regulatory responses, commercial manufacturing process control and monitoring, investigations, and process optimization.
  • Partner with IT Data/AI and CMC to establish process data governance, stewardship, and data products on the enterprise data platform for CMC analytics and AI/ML.
  • Own end-to-end lifecycle accountability for CMC applications, from strategy and design through deployment, sustainment, upgrades, continuous improvement, and retirement; partner with the business on business cases and outcomes and manage total cost of ownership.
  • Ensure systems meet GxP, data integrity, and global regulatory requirements, including FDA 21 CFR, and maintain audit readiness.
  • Drive operational excellence in reliability, performance, compliance, and support for CMC systems such as Empower, SoftMax Pro, Emerson Process Knowledge Management, and QbDVision.
  • Lead and mentor cross-functional and IT resources; oversee end-to-end initiative delivery and build partnerships with business stakeholders, IT teams, vendors, and procurement.

Desired Qualifications

  • A master’s degree, MBA, or PhD.
  • Working knowledge of EDI, APIs, system integration, and data transfers.
  • Experience with Agile and Scrum methodologies, using Jira or similar tools to track project risks, issues, tasks, and user stories, and knowledge of project management best practices.
  • Familiarity with emerging AI, data, and digital capabilities, including data models, data lakehouse architecture, knowledge graphs, agentic AI, and large language models.
  • Exceptional stakeholder management and influencing skills with operations leaders and scientist users, plus change management and transformation leadership.
  • A strategic mindset with a pragmatic approach to balancing long-term vision with reliable delivery of measurable business outcomes.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs